secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2026-06-02T11:05:16+00:00
Accession:  0001193125-26-252475
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026
--------------------------------------------------------------------------------

- FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.
- eGFR results now expected in the third quarter of 2026.
- Company plans to submit supplemental Biologics License Application for full approval in Q4 2026.
- Alignment could accelerate path to full approval for atacicept.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/0001193125-26-252475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/vera-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-252475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer